Pulmonology

Chronic pulmonary diseases, including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and acute respiratory distress syndrome (ARDS), represent a major global health challenge. MSC cell therapies offer a new approach to treating these conditions by reducing inflammation and promoting lung tissue regeneration.

Preclinical and clinical research shows that MSC cells reduce pulmonary inflammation, decrease fibrosis, and improve lung function. MSC cells secrete anti-inflammatory cytokines, growth factors, and exosomes that directly influence the regeneration of alveolar epithelial cells.

GaiaCell is developing inhalation and intravenous MSC preparations for pulmonary indications. Our manufacturing processes ensure high cell viability and optimal delivery of active biofactors to the site of injury.